At its June meeting, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended for approval a generic version of Atripla – Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan (efavirenz/emtricitabine/tenofovir disoproxil) for the treatment of HIV infection. Summary of opinion for Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan is available here. [gview ...

The Global Fund to Fight AIDS, Tuberculosis and Malaria is a major financier of national HIV responses and a vital source of prevention investments. By 2015, the Global Fund supported 3.6 million pregnant women to receive ARV prophylaxis to prevent transmission to their unborn children ...